After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic next year.

Ally Bridge Group led the round, which saw participation from Sinopharm Capital

Read the full 498 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE